## Rogelio Apiquian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1268534/publications.pdf

Version: 2024-02-01

623734 642732 32 550 14 23 g-index citations h-index papers 33 33 33 767 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients. Schizophrenia Research, 2005, 72, 123-129.	2.0	69
2	Personality and Clinical Predictors of Recurrence of Depression. Psychiatric Services, 1999, 50, 376-380.	2.0	53
3	Violent behavior in schizophrenic patients: relationship with clinical symptoms. Aggressive Behavior, 2005, 31, 511-520.	2.4	41
4	Frontal and limbic metabolic differences in subjects selected according to genetic variation of the SLC6A4 gene polymorphism. Neurolmage, 2005, 25, 1197-1204.	4.2	40
5	Association Study of MAO-A and DRD4 Genes in Schizophrenic Patients with Aggressive Behavior. Neuropsychobiology, 2007, 55, 171-175.	1.9	37
6	Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophrenia Research, 2009, 112, 181-186.	2.0	36
7	Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone. Neuropsychopharmacology, 2005, 30, 2236-2244.	5.4	28
8	Temperament and character in violent schizophrenic patients. Schizophrenia Research, 2007, 94, 74-80.	2.0	28
9	Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. International Journal of Neuropsychopharmacology, 2003, 6, 403-408.	2.1	19
10	Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry, 2004, 4, 12.	2.6	19
11	Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. Schizophrenia Research, 2003, 59, 35-39.	2.0	18
12	Variations of rest–Âactivity rhythm and sleep–Âwake in schizophrenic patients versus healthy subjects: An actigraphic comparative study. Biological Rhythm Research, 2008, 39, 69-78.	0.9	18
13	The P50 auditory evoked potential in violent and non-violent patients with schizophrenia. Schizophrenia Research, 2007, 97, 128-136.	2.0	17
14	Premorbid adjustment and violent behavior in schizophrenic patients. Schizophrenia Research, 2004, 69, 143-148.	2.0	15
15	Association analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patients. Psychiatry Research, 2007, 153, 209-215.	3.3	14
16	The Mexican first-episode psychotic study: clinical characteristics and premorbid adjustment. Schizophrenia Research, 2002, 53, 161-163.	2.0	13
17	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatric Disease and Treatment, 2010, 7, 19.	2.2	12
18	A video game for the neuropsychological screening of children. Entertainment Computing, 2017, 20, 1-9.	2.9	11

#	Article	IF	CITATIONS
19	Dopamine D4 Receptor (DRD4) Gene Polymorphism in the First Psychotic Episode. Archives of Medical Research, 2001, 32, 35-38.	3.3	10
20	The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. BMC Psychiatry, 2005, 5, 22.	2.6	10
21	APOE- $\hat{l}\mu$ 3 and APOE-219G Haplotypes Increase the Risk for Schizophrenia in Sibling Pairs. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 440-444.	1.8	7
22	Validity and reliability of the Spanish version of the Personal and Social Performance scale in adolescents with schizophrenia. Schizophrenia Research, 2015, 164, 176-180.	2.0	6
23	Similarities and Differences in Associations Between Duration of Untreated Psychosis (DUP) and Demographic, Premorbid, and Symptom Severity Measures in Two Samples of First-Episode Psychosis Patients from Mexico and the United States. Psychiatric Quarterly, 2020, 91, 769-781.	2.1	5
24	Lack of Association of Apolipoprotein E Polymorphism in Obsessive-Compulsive Disorder. CNS Spectrums, 2001, 6, 978-979, 992.	1.2	4
25	Association study of DRD3 gene in schizophrenia in Mexican sib-pairs. Psychiatry Research, 2011, 190, 367-368.	3.3	4
26	Cognitive impairment and its improvement after six months in adolescents with schizophrenia. Schizophrenia Research: Cognition, 2019, 17, 100135.	1.3	4
27	Standardization and validity of Chefmania, a video game designed as a cognitive screening test for children. Humanities and Social Sciences Communications, 2020, 7, .	2.9	4
28	Neuropsychological screening with TOWI: Performance in 6- to 12-year-old children. Applied Neuropsychology: Child, 2022, 11, 115-124.	1.4	3
29	Typical antipsychotics: The threshold doses strategy. European Neuropsychopharmacology, 1996, 6, 199.	0.7	2
30	Effectiveness of a treatment guideline for schizophrenia in adolescents: Lessons from a middle-income country. Australian and New Zealand Journal of Psychiatry, 2018, 52, 192-199.	2.3	2
31	Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clÃnicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento. Salud Mental, 2013, 36, 19.	0.3	1
32	Perception of non-imputability in schizophrenia in adolescents of Mexico City. Spanish Journal of Legal Medicine, 2019, 45, 48-51.	0.2	0